| Bioactivity | PI3Kα-IN-8 (Compound 9g) is a selective PI3Kα inhibitor with an IC50 of 0.012 μM. PI3Kα-IN-8 increases intracellular reactive oxygen species level, decreases mitochondrial membrane potential and induces apoptosis[1]. |
| Invitro | PI3Kα-IN-8 (Compound 9g) exhibits anticancer activity with IC50 values of 0.18 ± 0.03, 0.43 ± 0.05, 0.71 ± 0.08 and 0.63 ± 0.09 μM against HCT-116, MCF-7, HeLa and HepG2 cells, respectively[1].PI3Kα-IN-8 upregulates Bax and cleaved caspase-3/9 levels, and downregulates Bcl-2 level[1]. |
| Name | PI3Kα-IN-8 |
| Formula | C26H27BrN4O2 |
| Molar Mass | 507.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yang YQ, et al. Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3Kα inhibitors. Bioorg Chem. 2020 Jul;100:103845. |